Sai Akshaya Hodigere Balasubramanya
Overview
Explore the profile of Sai Akshaya Hodigere Balasubramanya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
3415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rehman H, Chandrashekar D, Balabhadrapatruni C, Nepal S, Balasubramanya S, Shelton A, et al.
JCI Insight
. 2022 Jul;
7(16).
PMID: 35852858
Metastatic urothelial carcinoma is generally incurable with current systemic therapies. Chromatin modifiers are frequently mutated in bladder cancer, with ARID1A-inactivating mutations present in about 20% of tumors. EZH2, a histone...
2.
Agarwal S, Chakravarthi B, Kim H, Gupta N, Hale K, Balasubramanya S, et al.
Transl Oncol
. 2020 May;
13(7):100776.
PMID: 32422575
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with an extremely poor prognosis. There is an urgent need to identify new therapeutic targets and also understand the mechanism of PDAC...
3.
Chandrashekar D, Chakravarthi B, Robinson A, Anderson J, Agarwal S, Balasubramanya S, et al.
Oncogene
. 2020 Apr;
39(20):4077-4091.
PMID: 32231273
Muscle-invasive bladder carcinomas (MIBCs) are aggressive genitourinary malignancies. Metastatic urothelial carcinoma of the bladder is generally incurable by current chemotherapy and leads to early mortality. Recent studies have identified molecular...
4.
Chakravarthi B, Pena M, Agarwal S, Chandrashekar D, Balasubramanya S, Jabboure F, et al.
Neoplasia
. 2018 Aug;
20(9):894-904.
PMID: 30121007
Genomic and transcriptome sequencing of bladder cancer (BLCA) has identified multiple molecular alterations during cancer progression. Many of these identified genetic and epigenetic changes play a role in the progression...
5.
Chakravarthi B, Chandrashekar D, Balasubramanya S, Robinson A, Carskadon S, Rao U, et al.
Prostate
. 2018 Jul;
78(16):1311-1320.
PMID: 30051493
Prostate cancer (PCa) is one of the most frequently diagnosed cancers among men. Many molecular changes have been detailed during PCa progression. The gene encoding the transcription factor ERG shows...
6.
Chakravarthi B, Goswami M, Pathi S, Dodson M, Chandrashekar D, Agarwal S, et al.
Prostate
. 2018 May;
78(9):693-694.
PMID: 29744932
No abstract available.
7.
Chakravarthi B, Chandrashekar D, Agarwal S, Balasubramanya S, Pathi S, Goswami M, et al.
Mol Cancer Res
. 2017 Oct;
16(7):1125-1137.
PMID: 29025958
In aggressive prostate cancers, the oncoprotein STMN1 (also known as stathmin 1 and oncoprotein 18) is often overexpressed. STMN1 is involved in various cellular processes, including cell proliferation, motility, and...
8.
Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B, et al.
Neoplasia
. 2017 Jul;
19(8):649-658.
PMID: 28732212
Genomics data from The Cancer Genome Atlas (TCGA) project has led to the comprehensive molecular characterization of multiple cancer types. The large sample numbers in TCGA offer an excellent opportunity...
9.
Chakravarthi B, Goswami M, Pathi S, Dodson M, Chandrashekar D, Agarwal S, et al.
Prostate
. 2016 Aug;
77(1):10-21.
PMID: 27550065
Background: Our goal was to investigate de novo purine biosynthetic gene PAICS expression and evaluate its role in prostate cancer progression. Methods: Next-generation sequencing, qRTPCR and immunoblot analysis revealed an...